NewAmsterdam Pharma Company N.V. (NAMS) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $19.92 (-4.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 6, 2026 | Roanna Ruiz | Leerink Partners | $55.00 | +176.1% |
| Oct 20, 2025 | Joseph Pantginis | H.C. Wainwright | $52.00 | +161.0% |
| Dec 30, 2024 | Ed Arce | H.C. Wainwright | $48.00 | +141.0% |
| Nov 20, 2024 | Roanna Ruiz | Leerink Partners | $45.00 | +125.9% |
| Sep 23, 2024 | Yasmeen Rahimi | Piper Sandler | $37.00 | +85.7% |
| Aug 28, 2024 | Serge Belanger | Needham | $36.00 | +80.7% |
Top Analysts Covering NAMS
NAMS vs Sector & Market
| Metric | NAMS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 4 | 8 | 19 |
| Target Upside | +157.7% | +153002.0% | +21.5% |
| P/E Ratio | -16.12 | 3.49 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $16M | $16M | $16M | 4 |
| 2027-03-31 | $4M | $4M | $4M | 4 |
| 2027-06-30 | $7M | $7M | $7M | 3 |
| 2027-09-30 | $28M | $28M | $28M | 3 |
| 2027-12-31 | $74M | $74M | $74M | 3 |
| 2028-12-31 | $88M | $382M | $1.20B | 3 |
| 2029-12-31 | $165M | $720M | $2.26B | 4 |
| 2030-12-31 | $249M | $1.08B | $3.39B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.46 | $-0.46 | $-0.46 | 6 |
| 2027-03-31 | $-0.51 | $-0.51 | $-0.51 | 3 |
| 2027-06-30 | $-0.52 | $-0.52 | $-0.52 | 5 |
| 2027-09-30 | $-0.42 | $-0.42 | $-0.42 | 3 |
| 2027-12-31 | $-0.17 | $-0.17 | $-0.17 | 6 |
| 2028-12-31 | $-0.81 | $-0.22 | $0.00 | 7 |
| 2029-12-31 | $-0.00 | $1.59 | $6.00 | 6 |
| 2030-12-31 | $-0.01 | $3.66 | $13.82 | 6 |
Frequently Asked Questions
What is the analyst consensus for NAMS?
The consensus among 4 analysts covering NewAmsterdam Pharma Company N.V. (NAMS) is Buy with an average price target of $51.33.
What is the highest price target for NAMS?
The highest price target for NAMS is $55.00, set by Roanna Ruiz at Leerink Partners on 2026-01-06.
What is the lowest price target for NAMS?
The lowest price target for NAMS is $36.00, set by Serge Belanger at Needham on 2024-08-28.
How many analysts cover NAMS?
4 analysts have issued ratings for NewAmsterdam Pharma Company N.V. in the past 12 months.
Is NAMS a buy or sell right now?
Based on 4 analyst ratings, NAMS has a consensus rating of Buy (2.00/5) with a +157.7% upside to the consensus target of $51.33.
What are the earnings estimates for NAMS?
Analysts estimate NAMS will report EPS of $-0.46 for the period ending 2026-12-31, with revenue estimated at $16M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.